Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 3, March, p. 375–384

doi: 10.17219/acem/94136

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas

Lidia Babiak-Choroszczak1,A,B,C,D,E,F, Kaja Giżewska-Kacprzak1,A,C,D,E,F, Grażyna Dawid2,B,C,E,F, Elżbieta Gawrych1,D,E,F, Maciej Bagłaj3,D,E,F

1 Department of Pediatric and Oncological Surgery, Urology and Hand Surgery, Pomeranian Medical University, Szczecin, Poland

2 Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology of Developmental Age, Pomeranian Medical University, Szczecin, Poland

3 Department of Pediatric Surgery and Urology, Wroclaw Medical University, Poland

Abstract

Background. Propranolol is an effective method of treatment for infantile hemangiomas (IH). A recent concern is a shift of the therapy into outpatient settings.
Objectives. The aim of the study was to evaluate the safety of initiating and maintaining propranolol therapy for IH.
Material and Methods. The study involved 55 consecutive children with IH being treated with propranolol. The patients were assessed in the hospital at the initiation of the therapy and later in outpatient settings during and after the therapy. Each time, the following monitoring methods were used: physical examination, cardiac ultrasound (ECHO), electrocardiography (ECG), blood pressure (BP), heart rate (HR), and biochemical parameters: blood count, blood glucose, aspartate transaminase (AST), alanine transaminase (ALT), and ionogram. The therapeutic dose of propranolol was 2.0 mg/kg/day divided into 2 doses.
Results. Four children were excluded during the qualification or the initiation of propranolol; a total of 51 patients were subject to the final analysis. All the children presented clinical improvement. There was a significant reduction in the mean HR values only at the initiation of propranolol. There were no changes in HR during the course of the therapy. Blood pressure values were within normal limits. Both systolic and diastolic values decreased in the first 3 months. Bradycardia and hypotension were observed sporadically, and they were asymptomatic. Electrocardiography did not show significant deviations. The pathological findings of the ECHO scans were not a contraindication to continuing the therapy. There were no changes in biochemical parameters. Apart from 1 symptomatic case of hypoglycemia, other low glucose episodes were asymptomatic and sporadic. The observed adverse effects were mild and the propranolol dose had to be adjusted in only 6 cases.
Conclusion. Propranolol is effective, safe and well-tolerated by children with IH. The positive results of the safety assessment support the strategy of initiating propranolol in outpatient settings. Future studies are needed to assess the benefits of the therapy in ambulatory conditions.

Key words

infantile hemangioma, propranolol, ECG monitoring, blood pressure, adverse effects

References (35)

  1. Janmohamed SR, de Waard-van der Spek FB, Madern GC, de Laat PC, Hop WC, Oranje AP. Scoring the proliferative activity of haemangioma of infancy: The Haemangioma Activity Score (HAS). Clin Exp Dermatol. 2011;36(7):715–723.
  2. Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: Clinical application of a new classification. J Pediatr Surg. 1983;18(6):894–900.
  3. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):26492651.
  4. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference. Pe-diatrics. 2013;131(1):128–140.
  5. Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: Recommendation of a European expert group. Eur J Pediatr. 2015;174(7):855–865.
  6. Babiak-Choroszczak L, Giżewska-Kacprzak K, Gawrych E, et al. Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas? Adv Clin Exp Med. 2018;27(5):703–710.
  7. Hengst M, Oelert M, Hoeger PH. Blood pressure monitoring during the induction and maintenance period of propranolol therapy for complicated infantile hemangiomas: A prospective study of 109 infants. Pediatr Dermatol. 2015;32(6):802–807.
  8. Wyrzykowski D, Bukowski M, Jaśkiewicz J. Guzy naczyniowe i wrodzone malformacje naczyniowe. Cancer Surgery. 2009;1(1):1–17.
  9. Rajewska J, Gawrych E, Fischer K, Walecka A, Brzosko M, Kwas A. Estimation of vascular endothelial growth factor and placental growth factor serum levels’ in infant with hemangioma and population of healthy infants. Ann Acad Med Stetin. 2012;58(2):5–10.
  10. Puttgen KB, Summerer B, Schneider J, Cohen BA, Boss EF, Bauman NM. Cardiovascular and blood glucose parameters in infants during pro-pranolol initiation for treatment of symptomatic infantile hemangiomas. Ann Otol Rhinol Laryngol. 2013;122(9):550–554.
  11. Liu LS, Sokoloff D, Antaya RJ. Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas: Is it indicated? Pediatr Dermatol. 2013;30(5):554–560.
  12. Cushing SL, Boucek RJ, Manning SC, Sidbury R, Perkins JA. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head Neck Surg. 2011;144(1):78–84.
  13. Hermans DJ, Bauland CG, Zweegers J, van Beynum IM, van der Vleuten CJ. Propranolol in a case series of 174 patients with complicated in-fantile haemangioma: Indications, safety and future directions. Br J Dermatol. 2013;168(4):837–843.
  14. Filippi L, Cavallaro G, Fiorini P. Propranolol concentrations after oral administration in term and preterm neonates. J Matern Fetal Neonatal Med. 2013;26(8):833–840.
  15. Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: A systematic review. Pediatr Dermatol. 2013;30(2):182–191.
  16. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: Risks and recommendations. Pediatr Dermatol. 2009;26(5):610–614.
  17. Przewratil P, Sitkiewicz A, Kierzkowska B, Lewandowska M, Lewandowska M, Andrzejewska E. Doświadczenia własne w leczeniu proprano-lolem naczyniaków wczesnodziecięcych – doniesienie wstępne. Med Wieku Rozwoj. 2011;15:406–413.
  18. You HS, Kim HS, Kim BS, Kim MB, Ko HC. Propranolol to treat infantile hemangioma (IH) in patients with congenital heart disease. J Am Acad Dermatol. 2015;72(5):912–914.
  19. Blei F, McElhinney DB, Guarini A, Presti S. Cardiac screening in infants with infantile hemangiomas before propranolol treatment. Pediatr Dermatol. 2014;31(4):465–470.
  20. Jacks SK, Kertesz NJ, Witman PM, Fernandez Faith E. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas. J Am Acad Dermatol. 2015;73(2):255–257.
  21. Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics. 2010;126(6):e1589–1593.
  22. Fusilli G, Merico G, Gurrado R, Rosa T, Acquafredda A, Cavallo L. Propranolol for infantile haemangiomas and neuroglycopenic seizures. Acta Paediatr. 2010;99(12):1756.
  23. Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010;146(7):775–778.
  24. Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N. Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol. 2010;27(2):195–196.
  25. Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: A case report. Pediatr Dermatol. 2011;28(2):169–171.
  26. Langley A, Pope B. Propranolol and central nervous system function: Potential implications for pediatric patients with infantile hemangiomas. Br J Dermatol. 2015;172(1):13–23.
  27. Vassallo P, Forte R, Di Mezza A, Magli A. Treatment of infantile capillary hemangioma of the eyelid with systemic propranolol. Am J Ophthalmol. 2013;155(1):165–170.
  28. Thoumazet F, Léauté-Labrèze C, Colin J. Mortemousque B. Efficacy of systemic propranolol for severe infantile haemangioma of the orbit and eyelid: A case study of eight patients. Br J Ophthalmol. 2012;96(3):370–374.
  29. Claerhout I, Buijsrogge M, Delbeke P, et al. The use of propranolol in the treatment of periocular infantile haemangiomas: A review. Br J Ophthalmol. 2011;95:1199–1202.
  30. Missoi TG, Lueder GT, Gilbertson K, Bayliss SJ. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol. 2011;129(7):899–903.
  31. Menezes MD, McCarter R, Greene EA, Bauman NM. Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. Ann Otol Rhinol Laryngol. 2011;120(10):686–695.
  32. Patel NJ, Bauman NM. How should propranolol be initiated for infantile hemangiomas: Inpatient versus outpatient? Laryngoscope. 2014;124(6):1279–1281.
  33. Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: A systematic review. Pediatrics. 2016;138(4):e20160353.
  34. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–746.
  35. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259–266.